DMH-1 free base · Synonyms: DMH 1 · DMH1

DMH-1 is a potent and selective BMP inhibitor.

For research use only. Not for human or veterinary use.

Target TGF-β Receptor Organoid Microtubule/Tubulin

Research area Cardiovascular Disease Neurological Disease

Purity >98% Stock Inquire

Data Sheet SDS COA

DMH-1 structure

CAS No.: 1206711-16-1

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
250 mg	USD 480.00	BP-01852-250mg	In stock	Get quote
500 mg	USD 650.00	BP-01852-500mg	In stock	Get quote
1 g	USD 1,020.00	BP-01852-1g	In stock	Get quote
5 g	Inquire	BP-01852-5g	Inquire	Inquire

Need another size or custom synthesis? Request a quote.

Description

DMH-1 is a potent and selective BMP inhibitor with IC50s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.

Biological activity

In Vitro DMH-1 (0.5 μM) induces the formation of beating embryoid bodies (EBs), with an efficiency of approximately 20% on day 7, peaking at approximately 75% on day 9. Its efficiency at all evaluated time points is significantly higher than that of the DMSO control group. DMH-1 (0.5 μM) specifically upregulates the expression profile of canonical cardiogenic genes, including BryT, Mesp1, Isl1 and Nkx2.5, and does not significantly induce the expression of non-cardiomyocyte mesodermal, endodermal or ectodermal markers compared with the DMSO control group. DMH-1 (0.5 μM; 24-48 h) does not induce cell apoptosis. DMH-1 (0.5-10 μM; 7 days) increases the expression of SOX1 in hiPSCs in a concentration-dependent manner. DMH-1 (0.5 μM) induces hiPSC-derived neural progenitor cells to differentiate into β3-tubulin-positive neurons.

Identifiers

SMILES: CC(C)OC1=CC=C(C=C1)C1=CN2N=CC(=C2N=C1)C1=CC=NC2=CC=CC=C12
InChIKey: JMIFGARJSWXZSH-UHFFFAOYSA-N

Specifications

MW (average): 380.4418
Formula: C₂₄H₂₀N₄O
CAS No.: 1206711-16-1
Physical state: Solid
Color: Off-white to yellow
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO

Documents

References

[1]. Engers DW, et al. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of mL347 as an ALK2 versus ALK3 selective mLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.

[2]. Sheng Y, et al. DMH1 (4-[6-(4-isopropoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline) inhibits chemotherapeutic drug-induced autophagy. Acta Pharm Sin B. 2015 Jul;5(4):330-6.

[3]. Neely MD, et al. DMH1, a highly selective small molecule BMP inhibitor promotes neurogenesis of hiPSCs: comparison of PAX6 and SOX1 expression during neural induction. ACS Chem Neurosci. 2012 Jun 20;3(6):482-91.

[4]. Hover LD, et al. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Cancer Lett. 2015 Nov 1;368(1):79-87.

[5]. Hao J, et al. DMH1, a small molecule inhibitor of BMP type i receptors, suppresses growth and invasion of lung cancer. PLoS One. 2014 Mar 6;9(6):e90748.

Same target

Search TGF-β Receptor

Same research area

Search Cardiovascular Disease